| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. | N Engl J Med | 2010 | 13.82 |
| 2 | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. | Lancet | 2012 | 4.25 |